相关实验视频

Updated: May 24, 2025

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

TP53-突变性急性髓性白血病:治疗和挑战的审查

Bipin Ghimire¹, Markie Zimmer¹, Vijayalakshmi Donthireddy¹

¹Department of Hematology and Oncology, Henry Ford Health, Detroit, Michigan, USA.

European journal of haematology

|March 4, 2025

概括

患有TP53突变急性髓性白血病 (AML) 的患者表现出治疗反应不佳. 本案例研究强调了这一高风险AML亚型的挑战,并探讨了治疗方案,强调了对新型治疗的需求.

科学领域:

血液学血液学血液学
在瘤学瘤学.
遗传学遗传学是一个

背景情况:

患有TP53突变 (TP53-MT) 的急性髓性白血病 (AML) 与预后不佳和对标准疗法的耐药性有关.
对TP53-MTAML的最佳治疗策略仍未确定,因此需要开发新的治疗方法.
TP53突变代表了AML的显著不良遗传因素,影响了患者的治疗结果.

研究的目的:

为了呈现一种耐火TP53-MTAML病例与骨髓发育不良.
根据患者对FLAG-Ida化疗的反应,探索TP53-MTAML的有效治疗方案.
审查关于TP53-MT AML治疗结果的现有文献.

主要方法:

一位患有TP53-MTAML的患者的病例报告.
进行强化化疗法 (脂质体鲁素和细胞氨酸,其次是FLAG-Ida).
对TP53-MTAML治疗研究的综合文献综述.

主要成果:

患者最初患有耐药性疾病,无法接受标准的诱导化疗.
患者获得了FLAG-Ida的第二次诱导化疗的最佳反应.
文献审查表明,定义治疗反应和治疗TP53-MTAML的挑战是复杂的.

结论:

由于其异质的遗传背景和反应率较低,TP53-MT AML 存在复杂的治疗挑战.
在这种耐火TP53-MTAML的特殊情况下,FLAG-Ida化疗已证明有效.
进一步研究新型疗法和治疗组合对于改善TP53-MTAML患者的治疗结果至关重要.

关键词:

这就是TP53的特点.急性骨髓性白血病 (AML) 是一种急性骨髓性白血病.骨髓发育不良症骨髓发育不良症在 p53 里,p53 是一个 p53 号码.

更多相关视频

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

相关概念视频

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...